NCT02074137 - Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

CABAZITAXEL XRP6258

Pharmaceutical form:Solution Route of administration: Intravenous

DRUG

Prednisone

Pharmaceutical form:Tablet Route of administration: Oral

DRUG

Prednisolone

Pharmaceutical form:Tablet Route of administration: Oral

Trial Locations (3)

Investigational Site Number 356003, New Delhi

Investigational Site Number 356002, Trivandrum

Investigational Site Number 356005, Kollkata